Derivative exercise or conversion — not an open-market buy.
Transaction Mar 19, 2025 · Disclosed Oct 5, 2025
14 different filers disclosed JNJ within 90 days. Disclosed 200 days after the transaction; reported as an official range, not an exact amount.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
$15,001 - $50,000
Official band as filed. No midpoint or exact amount is implied
Spouse
200 days
Days between the transaction date and the filing date
First disclosure on this company by this filer
14 distinct filers within 90 days
Sponsored 2 bills in Health this Congress.
Bills (H.R. / S.) this member sponsored in the 119th Congress so far, including any introduced after the trade, grouped by the policy area the Congressional Research Service assigned (Congress.gov). Which policy areas relate to which sectors is OQRO's editorial mapping. Not a sign of what they knew or why they traded
Derivative exercise or conversion — not an open-market buy.
32K → 11K shares held−67% of their stake
Johnson & Johnson's Innovative Medicine, R&D sold $4.19M of Johnson & Johnson shares. Nobody planned it ahead of time.
Derivative exercise or conversion — not an open-market buy.